| Literature DB >> 30962663 |
Takashi Tamura1, Asahi Hishida1, Kenji Wakai1.
Abstract
Previous epidemiological studies have shown that coffee consumption may reduce liver cancer risk. The present study aimed to summarize the evidence for this association in the Japanese population by performing a meta-analysis of the results of relevant cohort studies conducted in Japan. We searched studies published prior to September 1, 2018 in PubMed. Extracted data were analyzed using a random effects model. A total of six cohort studies from five publications were included in the final analysis. The pooled estimate of relative risk with 95% confidence interval (CI) for the group with highest coffee consumption was 0.50 (95% CI: 0.38-0.66, p < 0.001) compared with non-coffee drinkers or those who almost never drink coffee. No evidence of publication bias was observed (p for Begg's test = 0.85). This meta-analysis suggested that coffee consumption among Japanese people has a significant role in preventing liver cancer.Entities:
Keywords: Coffee; Cohort study; Japan; Liver cancer; Meta-analysis
Mesh:
Substances:
Year: 2019 PMID: 30962663 PMCID: PMC6433635 DOI: 10.18999/nagjms.81.1.143
Source DB: PubMed Journal: Nagoya J Med Sci ISSN: 0027-7622 Impact factor: 1.131
Fig. 1Flow diagram of the selection of studies included in the meta-analysis
Characteristics of included prospective cohort studies conducted in Japan for the association between coffee consumption and liver cancer risk
| Author | Cohort name | Population | Age | No. of cases | Cohort size | Duration of follow-up (years) | Coffee consumption | No. of cases/N | Relative risk
| Adjusted covariates | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| The highest consumption group | The lowest consumption group | ||||||||||
| Tamura et al
| Takayama Study | Japan | ≥35 | 172 | 30,824 | 16 | ≥Twice/d vs.
| 11/4,985 | 74/7,497 | 0.40
| Age, sex, alcohol intake, smoking, BMI, education, total energy intake, physical activity, and medical history of diabetes mellitus. |
| Inoue et al
| JPHC Study II | Japan | 40–69 | 110 | 18,815 | 12 | ≥3 cups/d vs.
| 6/1,646 | 51/6,324 | 0.54
| Age, sex, study areas, alcohol intake, smoking, BMI, green tea consumption, medical history of diabetes mellitus, serum ALT level, HCV infection, and HBV infection. |
| Ohishi et al
| Adult Health Studya | Japan | NA | 224 | 644 | 44 | Daily vs.
| N/A | N/A | 0.40
| Age, sex, alcohol intake, smoking, BMI, medical history of diabetes mellitus, radiation dose to the liver, HCV infection, and HBV infection. |
| Kurozawa et al
| JACC Study | Japan | 40–79 | 258 | 83,966 | 12 | ≥1 cup/d vs.
| 98/44,151 | 103/24,556 | 0.50
| Age, sex, alcohol intake, smoking, medical history of diabetes mellitus and liver diseases, and education. |
| Shimazu et al
| Japan Miyagi Prefecture, Cohort 1 | Japan | >40 | 70 | 22,404 | 9 | ≥1 cup/d vs.
| 16/7,959 | 29/4,938 | 0.53
| Age, sex, alcohol intake, smoking, and medical history of liver disease. |
| Japan Miyagi Prefecture, Cohort 2 | Japan | 40–64 | 47 | 38,703 | 8 | ≥1 cup/d vs.
| 14/17,619 | 12/6,954 | 0.68
| Age, sex, alcohol intake, smoking, and medical history of liver disease. | |
Abbreviation: JACC, the Japan Collaborative Cohort; JPHC, the Japan Public Health Center-based Prospective.
aNested case-control study.
Quality scores of included six cohort studies using Newcastle-Ottawa Scale
| Selection | Comparabilityb | Outcome | Overall score | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Cohort name | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Outcome of interest not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Follow-up long enough for outcomes to occurc | Adequacy of follow-up of cohortsd | |||||
| Tamura et al
| Takayama Study | * | * | – | * | * | * | * | * | * | 8 | |||
| Inoue et al
| JPHC Study II | – | – | – | * | * | * | * | * | * | 6 | |||
| Ohishi et al
| Adult Health Studya | – | – | – | * | * | * | * | * | – | 5 | |||
| Kurozawa et al
| JACC Study | – | – | – | * | * | * | * | * | – | 5 | |||
| Shimazu et al
| Japan Miyagi Prefecture, Cohort 1 | * | * | – | * | * | * | * | – | – | 6 | |||
| Japan Miyagi Prefecture, Cohort 2 | * | * | – | * | * | * | * | – | – | 6 | ||||
Abbreviation: JACC, the Japan Collaborative Cohort; JPHC, the Japan Public Health Center-based Prospective.
aNested case-control study.
bA maximum of two stars can be assigned for the “Comparability” category. One star was awarded if the study provided risk estimates with controlling for age and sex, with an additional star awarded if it controlled for other potential confounders including alcohol intake and smoking status.
cA study with the follow-up of 10 years or longer was awarded one star.
dA study with the follow-up rate of 80% or higher was awarded one star.
Fig. 2Forest plot of study-specific and pooled relative risks (RR) and 95% confidence intervals (CI) of liver cancer risk for the highest coffee consumption group compared with the lowest
Abbreviation: JACC, the Japan Collaborative Cohort; JPHC, the Japan Public Health Center-based Prospective.
*Nested case-control study.